OncBioMune Pharmaceuticals, Inc.
(OTCQB: OBMP) is a clinical-stage biopharmaceutical company engaged in the
development of novel cancer immunotherapy products. The company’s lead product
candidate, ProscaVax™, is a novel prostate cancer vaccine that’s scheduled to
commence a phase II clinical trial in the coming weeks after recording
promising results in its phase I clinical trial, which was completed late last
year.
Unlike many leading treatment
options, ProscaVax is being developed to treat prostate cancer in its early
stages, allowing patients to build up an immunity that helps their bodies
combat the disease with little or no toxicity. OncBioMune’s revolutionary
technology introduces molecules known as antigens into the body in order to
stimulate an aggressive immune response before the cancer becomes too advanced.
In its phase I clinical trial of ProscaVax, an impressive 70 percent of patients
who received three vaccines demonstrated increased immune response to
prostate-specific antigen (PSA), a protein produced by cells of the prostate
gland that can aid in the early detection of prostate cancer. This result, in
addition to the candidate’s exemplary safety profile, bodes well for ProscaVax
moving forward.
Leveraging a proprietary vaccine
technology designed to boost the immune system’s natural ability to protect the
body, ProscaVax is expected to be marketable and extremely profitable upon FDA
approval, potentially becoming the standard of care for prostate cancer
treatment. According to data from the American Cancer Society, about 220,800
new cases of prostate cancer were diagnosed in the United States last year. In
total, the disease accounts for more than 27,500 deaths each year, making it
the second leading cause of cancer death in American men.
Despite its prevalence, prostate
cancer remains one of the most survivable forms of cancer, with a 10-year
survival rate of roughly 98 percent in cases discovered in the local or
regional stages. However, survivability is greatly impacted if the disease goes
undetected into an advanced stage. In cases where prostate cancer has spread to
bones, organs or distant lymph nodes, the five-year survival rate drops from
nearly 100 percent to just 28 percent, according to ZERO. This statistic
further highlights the potential benefit of ProscaVax, particularly in early
stage prostate cancer cases.
Leading market research firm BCC
Research valued the global market for the prevention and treatment of prostate
cancer at $26.1 billion in 2011, and the firm forecasts the market to surpass
$50 billion by next year. This growth will be led by the drug therapeutics
sector, which is expected to sustain an 18 percent compound annual growth rate
through 2017. As OncBioMune prepares to commence its phase II clinical trial of
ProscaVax, this market performance could foreshadow an opportunity for the
company to achieve strong financial growth following FDA approval and commercialization
of its innovative treatment option.
Through an agreement with Lincoln
Park Capital Fund, OncBioMune has secured $10 million in funding with which to
help finance the upcoming phase II clinical study of ProscaVax. This strong
cash position, along with the early promise of the company’s cancer vaccine
technologies, makes OncBioMune an attractive play in the rapidly evolving
oncology space.
For more information, visit www.oncbiomune.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment